Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia.
Saved in:
| Title: | Dual targeting of EZH2 and EZH1 drives exit of leukemia stem cells from quiescence and potentiates chemotherapy in acute myeloid leukemia. |
|---|---|
| Authors: | Akiyama H; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nishida Y; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chang KH; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bedoy AD; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Muftuoglu M; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ma W; Department of Bioinformatics and computational biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Basyal M; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hirschi Z; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Honma D; Daiichi Sankyo, Co. Ltd., Tokyo, Japan., Tsutsumi S; Daiichi Sankyo, Co. Ltd., Tokyo, Japan., Wang J; Department of Bioinformatics and computational biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zhang W; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rampal RK; Department of Medicine, Leukemia Service, Center for Hematologic Malignancies, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Oluwole OO; Vanderbilt University Cancer Center, Nashville, TN, USA., Bixby DL; Comprehensive Cancer Center, University of Michigan, Grass Lake, MI, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Andreeff M; Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. mandreef@mdanderson.org. |
| Source: | Blood cancer journal [Blood Cancer J] 2025 Apr 24; Vol. 15 (1), pp. 76. Date of Electronic Publication: 2025 Apr 24. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
